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ORIGINAL ARTICLE
Challenges in evaluation of screening for gastric cancer among men based on
nonrandomized design
Ilkka Vohlonena, Matti H€ark€onenb, Nea Malilac,d, Eero Pukkalae,f, Pentti Sipponeng, Veli Koistinenh and
Matti Hakamai
aDepartment of Public Health, Health Policy, University of Eastern Finland, Kuopio, Finland; bDepartment of Clinical Chemistry, Clinical
Chemistry, University of Helsinki, Helsinki, Finland; cCancer Epidemiology, Finnish Cancer Registry, Helsinki, Finland; dSchool of Health
Sciences, University of Tampere, Tampere, Finland; eEpidemiology, Finnish Cancer Registry, Helsinki, Finland; fSchool of Health Sciences,
University of Tampere, Tampere, Finland; gDepartment of Pathology, Patolab Oy, Espoo, Finland; hDepartment of Biostatistics, Finnish
Consulting Group, Helsinki, Finland; iDepartment of Epidemiology, Finnish Cancer Registry, Helsinki, Finland
ABSTRACT
Background: Objective was to quantify biases in screening for gastric cancer when comparing attend-
ers to nonattenders using serum pepsinogen I (SPGI) level as primary test.
Methods: In mid 1990s, all men aged 51–65 years from two Finnish cities were invited to SPGI screen-
ing. Mortality and premature mortality in attenders were compared to nonattenders. Efficacy of screen-
ing was studied by 15 years’ follow-up of standardized mortality ratio (SMR) and potential years of life
lost (PYLL) due to gastric cancer. Bias due to selective attendance was quantified using corrective coef-
ficients based on total cancer incidence and mortality, and gastric cancer-specific incidence and mortal-
ity for total population and nonattenders.
Results: In 1994–1996, men aged 51–65 years (16,872) were invited to SPGI assay and 12,175 men
(72%) attended. SPGI was 25 microg/l or less in 610 (5%) men, indicating severe atrophic gastritis (AG).
Post-screening gastroscopy was performed to 435 men with low SPGI. Of these, 168 men were referred
for treatment due to abnormal focal lesions. Attributable proportions in reductions of SMR and PYLL
from gastric cancer due to screening were 59% and 67%. After correcting for selective participation,
attributable proportions were reduced to 23% and 39%.
Conclusions: Biomarker screening by low SPGI among middle-aged men followed by upper gastro-
intestinal endoscopy decreased long-term and premature mortality due to gastric cancer. However, in
spite of methodological corrections done, the results do not justify any firm conclusions or recommend
general screening programs. Randomized trials are warranted for this purpose.
Abbreviations: SPGI: serum pepsinogen I; AG: atrophic gastritis; SMR: standardized mortality ratio; SIR:
standardized incidence ratio; PYLL: potential years of life lost
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Introduction
In Finland, a population-based sample of middle-aged men
from two cities was invited in 1994–1996, to investigate
whether a serum pepsinogen I (SPGI) screening, followed by
upper gastrointestinal (GI) endoscopy in those with low SPGI,
can be applied as a public health program. It was known
that SPGI levels of 25 microg/l or less indicate advanced
(moderate or severe) atrophic gastritis (AG) in the gastric cor-
pus and fundus with high reliability [1–4]. However, the indi-
cators of structure, process, and outcome related to
screening were completely unknown.
The objective of this study was to find out whether the
recent laboratory evidence of the etiological role of SPGI was
sufficient to start screening and to quantify challenges due
to bias in the evaluative design. The screening was based on
personal invitation of the target population but it did not
contain any controls. We studied gastric cancer mortality by
comparing the attenders in screening with the nonattenders
over more than 15 years (from 1994 to 2011) after screening
in 1994–1996. Since the design did not allow for a non-
biased assessment of efficacy, statistical corrections were per-
formed to adjust for the effects of selective participation.
Material and methods
Study population and study cohorts
All 16,872 men born in 1929–1943 and living in 1994–1996
in two Finnish cities (Kotka and Vantaa) were identified by
population registry, and were invited to give a blood sample
(serum) for the SPGI test: half of them in autumn 1994 and
the remainder in autumn 1996 (Table 1). Altogether, 12,175
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men (72%) attended the SPGI screening and 4697 did not.
They form the attenders (screened) and nonattenders (not
screened) in the present investigation, respectively (Figure 1).
Blood sampling and SPGI test
The men were invited by mail to visit municipal health cen-
ters for blood sampling drawn by experienced laboratory
nurses. Fasting sera were collected in aprotinin (Trasylol,
Bayer Germany, 200 KIE/ml) containing Venoject tubes and
stored at –70 C until analyzed. SPGI was analyzed using
the specific ELISA tests provided by Biohit Oyj, Helsinki,
Finland. The assay has been calibrated to correspond to
results obtained by radioimmunoassay (RIA) used by Samloff
in 1982 using 238 serum samples with serum pepsinogen
concentrations between 1.5 and 120 microg/L. The clinical
sensitivity and specificity for advanced AG are 92% and
90% for the test, respectively, according to the man-
ufacturer’s kit instructions for use. The screening was
approved by the Ethics Committee of the University
Hospital of Kuopio in 1994.
Low SPGI levels (25 microg/l or lower), indicating the pres-
ence of advanced (moderate or severe) AG in gastric corpus
and fundus, were found in 610 men (5% of the screened
men). Men with low SPGI levels were contacted by telephone
and invited to gastroscopy unless they had medical
contraindications.
Screening endoscopy in 1994–1996
A diagnostic upper GI endoscopy (screening gastroscopy)
was performed in 435 SPGI-test positive men; i.e., 71% of the
men with a low SPGI (Figure 1). All these endoscopies were
performed by one experienced clinician. In endoscopy, biop-
sies from the stomach were collected: two from the antrum
and two from the corpus, according to the guidelines of the
Sydney System. Specimens for histopathology were also
taken from all focal abnormalities (e.g., erosions, ulcers, nod-
ules, polyps, masses, unusual color spots, etc.) seen by an
endoscopist in the stomach mucosa. In all, 168 men (1.4% of
all men in the screened cohort) were referred for further clin-
ical treatment or surveillance. Of these, 56 men had focal
gastric lesions with abnormal and atypical morphology in
biopsy pathology, and all these were considered potentially
cancerous or precancerous lesions (Figure 1).
Follow-up and collection of mortality data in 1994–2011
Long-term follow-up of all men invited for screening in
1994–1996 was run for cancer incidence, deaths, or emigra-
tion. These men formed the attenders (screened) and nonat-
tenders (nonscreened) cohorts as explained above. The
follow-up started the month after start of screening (on 1
December 1994 for the half of the men and on 1 November
Figure 1. Design of the feasibility study on screening for gastric cancer in middle-aged men in two Finnish cities in 1994–1996 using a biomarker.
Table 1. Number and percentage of men, number of accumulated person
years, and mean time per person in follow-up in 1994–2011 by screening
status.
Men Person years
Screening status Number Percent Number Mean/person
Non-screened 4697 27.8 54,955 11.7
Screened 12,175 72.2 166,798 13.7
Total invited 16,872 100.0 221,023 13.1
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1996 for the other half) and ended at death, emigration or
on 31 December 2011 (Table 1). Information on gastric can-
cer cases and deaths in the cohorts was received from the
Finnish Cancer Registry (FCR) and data on emigration and
date of death was from the population register. The cause of
death information originates from Statistics Finland [5]. The
individuals in the study were linked to registers using the
national personal identity code of all Finnish residents.
Due to mandatory reporting of all cancer diagnoses in
Finland, the FCR has a good national coverage of over 99%
of solid cancer cases in Finland [6–8]. The registry includes
data of all gastric cancer cases (topography code C16 in ICD-
O-3) but it does not include data of cases classified as nonin-
vasive premalignant lesions (dysplasia or intramucosal neo-
plasia). The cancer information used in this study included
the date of diagnosis, topography, morphology, and data
indicating whether the cancer patient died from the cancer
in question or from any other cause.
Statistical methods
The standardized mortality ratios (SMRs) and potential years
of life lost (PYLL) were calculated for gastric cancer and for
all cancers combined (cancer at any site) [6,9] for attenders
and nonattenders separately. In order to calculate the SMR,
the observed numbers of death were compared with the
expected numbers among the attenders and nonattenders.
The expected numbers for each age group (5-year age cate-
gories) and 4-year calendar period were estimated by multi-
plying the number of person years in the category
accumulated among the attenders and the nonattenders
cohorts with the respective mortality rate in the total male
population in Finland. The 95% confidence intervals for
SMRs were estimated assuming a Poisson distribution for
the numbers of observed deaths. Standardized Incidence
Ratios (SIRs) were calculated according to the same princi-
ples as SMRs.
PYLL is an indicator of premature mortality. It represents
the total number of life years lost (not lived) by an individual
who was not assumed to die by a given age. The PYLL-value
was calculated for each dead person as the difference
between the observed date of death and the expected
length of life. In the calculation of PYLL-values, the expected
length of life was set at the Finnish average standard (80
years). Those men who died after their 80-year-old birthday
did not contribute to the PYLL value in any way. PYLL-values
were classified according to the cause of death (stomach
cancer or all cancers) and reported per 1000 persons and per
death among the screened and the non-screened.
Statistical analyses
Due to selective attendance, the effect of screening, i.e., effi-
cacy, was measured by two types of attributable proportions
in reductions of SMR and PYLL, the crude rates and the cor-
rected rates. In analyses of the attributable proportions in
reductions of SMR and PYLL, the differences in the geo-
graphic (e.g., supply and use of health services), social (e.g.,
demographic and etiological), and health (e.g., earlier diagno-
ses) characteristics of the men between the two cohorts
were corrected for, since the potential self-selection corre-
lates with the probability of death from gastric cancer. The
regional differences (health care supply) and the general risks
of any cancer were corrected for by taking into account the
standardized incidence ratios and SMRs for all cancers of the
total population and of the nonattenders, as described
below.
In order to adjust for self-selection, we denote:
M¼ SMR or PYLL due to gastric cancer,
I¼ SIR of gastric cancer,
a¼ those screened,
an¼ those not screened,
m¼ SMR or PYLL due to all cancers,
i¼ SIR of all cancers,
E1¼ crude effect (attributable proportion),
E2¼ effect with correction for selection and confounding
factors (corrected attributable proportion).
The crude estimate of the effect (E1) was estimated as:
E1¼ 1 – (Man/Mn).
The corrected estimate of the effect (E2) was estimated as:
E2¼ 1 – (Ian/Ia) (Man/Mn) (maan/ma)(ian/in).
Selection bias was corrected by the relative risk of back-
ground incidence of gastric cancer in screened and non-
screened cohorts (Ian/Ia). Furthermore, those attending
screening may have a better general health and a more
favorable prognosis than those not attending. We assumed
that these biases are seen in the survival and in the ratio of
cancer mortality to cancer incidence (m/i) in the cohorts, jus-
tifying the correction factor (man ia)/(ma ian). The same for-
mulae were used for correcting the differences in reductions
of PYLL values due to stomach cancer between the attenders
and nonattenders cohorts by adjusting for PYLL values for
all cancers.
The mortality analyses of gastric and all cancers were first
performed with refined SMRs, i.e., excluding deaths from gas-
tric cancer diagnosed before the beginning of the follow-up.
There were only four such deaths in the present series. The
refined and the crude SMR rates of all gastric cancer deaths
turned out to be similar independently of time of the diag-
nosis. Only the crude SMRs and PYLL values were presented
including all gastric cancers without considering the timing
of diagnosis.
Results
The SMRs and SIRs for all cancers combined (cancers at all
sites) and for gastric cancer separately in both study cohorts
are presented in Table 2. SMR for gastric cancer (0.53) was
significantly below unity in the attender cohort and it was
higher in the nonattenders cohort (SMR 1.28). The SMR for all
cancers in the attender cohort was 0.91 and in the nonat-
tenders cohort 1.45.
The SIRs for all cancers were roughly similar in both study
cohorts. However, in the attender cohort, the SIR for stomach
cancer was lower than expected (0.75, 95% CI 0.57–0.95) and
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it was lower in the attenders than in the nonattenders cohort
(0.88, 95% CI 0.56–1.32) (Table 2).
The PYLL value for gastric cancer was significantly lower
among the attenders (27.7, 95% CI 15.5–36.0) than among
the nonattenders (77.3 95% CI 43.1–111.4) cohort (Table 3).
Again, the PYLL value for all cancers was lower in the
attender cohort than in the nonattenders cohort but this dif-
ference was smaller than the difference in PYLL for gastric
cancer.
The crude and corrected effects of screening on mortality
and prolongation of life are given in Table 4. The relative
decrease in SMR attributable to SPGI screening for gastric
cancer resulted in a value 0.59 for the crude proportion (E1).
The corresponding crude attributable proportion for PYLL
was 0.67. After correcting for selection bias, the corrected
attributable proportions (E2) for SMR and PYLL were 0.23 and
0.39, respectively (Table 4).
Discussion
Gastric cancer is one of the common cancers with high mor-
tality worldwide. The age-adjusted incidence rate (world
standard) in 2013 among Finnish men was 6 per 100 000
person years, which is one-tenth of the respective rate in the
1950s [10]. The life expectancy of patients with gastric cancer
is not long, unless the cancer is diagnosed in its early stage.
In 2009–2013, the five-year relative survival ratio in males
with stomach cancer in Finland was 23% [10]. About a half
of gastric cancers, being most often of the so-called intestinal
type, are considered to develop in AG and an acid-free stom-
ach via the ‘Correa cascade’ [11–14]. Therefore, early identifi-
cation and endoscopy of subjects with AG may facilitate the
diagnosis of gastric cancer at an early stage, and may enable
treatment of premalignant gastric lesions (intramucosal neo-
plasias) in an asymptomatic phase [6–9]. A low serum level
of pepsinogen I (SPGI) is a reliable biomarker of AG and is,
therefore, a tool to noninvasively delineate subjects with
advanced AG who need a prompt diagnostic upper GI endos-
copy because of increased cancer risk [1–4]. Correspondingly,
it is conceivable that an early diagnosis of AG with a bio-
marker test followed with a diagnostic upper GI endoscopy
will improve the cancer survival, resulting also in decrease of
premature mortality.
In order to develop a program of screening for stomach
cancer by a biomarker, this study comprised a large popula-
tion-based sample of men born in 1929–1943 who were
invited to screening by SPGI/endoscopy in 1994–1996 in two
Finnish cities. This screening program applying a simple SPGI
biomarker blood test was well accepted with a high partici-
pation percentage (72%) and the screening process was
adequate. Here we evaluate whether the design was
adequate for evaluation of the efficacy of the screening pro-
gram by gastric cancer mortality.
Biases between the attenders and nonattenders cohorts
constitute a dilemma in assessment of the efficacy of the
screening. Because the screening trial could not be imple-
mented to allow comparison of invited and non-invited
groups of men, the only option was to try to correct for the
effects of selective attendance afterwards using general indi-
cators of cancer frequency and mortality in the categories to
be compared.
In general, the reports of screening programs on cancers
do not include data or attempts to correct for selection
biases even though they are certainly noteworthy in all
screening projects [8,15]. The men who did not want to par-
ticipate in the SPGI test may have been less interested in
health issues in general than those who participated and
were, therefore, more liable to early death from gastric can-
cer and to high mortality from any cause of death [16–20].
The men in the present nonattender cohort had a clearly
higher incidence (SIR) of gastric cancer and of all cancers
than those in the attender cohort. In spite of the corrections
afterwards, there may still remain biases that could not be
taken into account.
Table 3. Potential years of life lost (PYLL values) per 1000 persons and mean PYLL values per death before age of 80 among the screened
and non-screened men by site of cancer 1994–2011.
Screened (n¼ 12,175) Non-screened (n¼ 4697)
Cancer site PYLL 95%CI PYLL/death PYLL 95%CI PYLL/death
Gastric cancer 25.7 15.5–36.0 10.4 77.3 43.1–111.4 15.1
All cancers 875 815–935 11.0 1388 1259–1518 13.2
Table 4. Crude and corrected proportions (%) in reduction of
mortality and of potential years of life lost (PYLL) among men
attributable to SPGI screening.
Attributable proportion (%)
Outcome indicator Crude (E1) Corrected (E2)
Mortality 59 23
PYLL 67 39
Table 2. Standardized mortality ratios (SMR) and standardized incidence ratios (SIR) among the screened and non-screened men by the site of cancer
1994–2011.
Screened (N¼ 12,175) Non-screened (n¼ 4697)
Cancer site Event OBS EXP SMR or SIR 95%CI OBS EXP SMR or SIR 95%CI
Stomach cancer Deaths 31 58.1 0.53a 0.36–0.75 24 18.7 1.28 0.82–1.90
Cases 60 80.5 0.75 0.57–0.95 23 26.1 0.88 0.56–1.32
All cancers Deaths 1 020 1 116.7 0.91 0.86–0.97 514 354.8 1.45 1.33–1.57
Cases 3 088 2 747.6 1.12 1.08–1.16 976 881.4 1.11 1.04–1.17
ap< 0.001.
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The present study suggests that biomarker screening by
SPGI may reduce mortality from gastric cancer by one-fifth
over 15 years. Correspondingly, screening was estimated to
reduce the potential years of life-lost (PYLL) due to gastric
cancer by almost 40%. These estimates were, however, incon-
clusive due to methodological issues as described above.
In our study, two cases of gastric cancer were found by
screening in men with low SPGI in 1994-1996, and both
patients died from gastric cancer within 5 years. Therefore,
the long term decrease in mortality between 1994 and 2011
was likely due to treatment of pre-cancerous lesions
observed in screening endoscopy or were due to eradication
of the on-going Helicobacter pylori infection [16–20]. It can
be assumed that the precancerous lesions in an atrophic
stomach mucosa develop to invasive cancers during life-time
in up to one third of cases if the lesions are not properly
treated [20].
In our study, the expected number of deaths due to gas-
tric cancer was 58 and this number was based on a forecast
made on the basis of the Finnish Cancer Registry. In the
screening for gastric cancer by a biomarker, we found 56
lesions and 2 cases of gastric cancer. In this view, expected
and observed cases of gastric cancer were similar.
This observation indicates, that at least some 20 men
would be at risk of gastric cancer among the 56 men who
were diagnosed with a precancerous lesion. Based on the
observed gastric cancer deaths, the crude attributable pro-
portion in reduction of deaths due to gastric cancer was 59%
and therefore 16 deaths due to gastric cancer were pre-
vented if attendance was not selective. Because of selection,
we corrected it in the analyzes and the corrected attributable
proportion was 23% with the observed reduction of 6 deaths
due to gastric cancer. We cannot regard this figure as an
unbiased one, because the unknown potential of residual
confounding after the methodological corrections. Hence we
do not know whether the screening for gastric cancer was
efficacious or not.
Analyzes of the effects of SPGI screening on premature
gastric cancer mortality using PYLL gave results consistent
with those obtained by cancer mortality. The corrected attrib-
utable proportion of SPGI screening in reduction of PYLL for
gastric cancer was 39%. PYLL is dependent on the value for
life expectancy selected for the calculations. In the present
investigation, a life expectancy of 80 years was selected.
Deaths before this age are considered premature and most
deaths due to gastric cancer in Finland occur before age
of 80.
The greater reduction in corrected attributable proportion
in reduction of PYLL than of SMR for gastric cancer (39% vs.
23%) may indicate that some cancerous lesions among the
attending were observed and treated in early and curable
stages.
In spite of the association between SPGI screening and
decreased gastric cancer mortality and PYLL, the present
results may still be biased although methodological correc-
tions were done to correct for confounding. Therefore, the
present results do not justify definitive conclusions or imple-
mentation of general screening programs. Information on
efficacy of a new and potential screening technology for
cancer needs to be based on well-designed study protocols
which result in unbiased evidence. Therefore, controlled and
randomized screening studies are an ultimate prerequisite. In
the developed countries, incidence of gastric cancer is
decreasing along with H. pylori infection and AG, but in the
developing countries these are still major public health
problems.
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